Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VIR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Departure of CFO (new) — The CFO is leaving the company to pursue another opportunity.
Vir Biotechnology CFO Jason O'Byrne resigns; CAO Brent Sabatini named interim CFO
Filed July 24, 2026 · Period ending July 20, 2026 · ~1 min read
Key Changes
-
high
CFO Jason O'Byrne resigned effective August 3, 2026, to pursue another opportunity; company states departure not due to disagreement on operations, policies, or practices.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR → -
medium
Brent Sabatini, Senior VP and Chief Accounting Officer since February 2023, appointed interim principal financial officer effective August 3; no additional compensation for interim role.
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation verify on EDGAR →
Summary
Vir Biotechnology disclosed that CFO Jason O'Byrne will step down August 3, 2026, to pursue another opportunity. The company emphasized his resignation was not due to any disagreement on operations, policies, or practices, and has initiated a search for a permanent successor. Brent Sabatini, who has served as Senior VP and Chief Accounting Officer since February 2023 and principal accounting officer since October 2024, will assume the interim CFO role without additional compensation.
CFO departures warrant attention because they can signal internal issues or strategic shifts, though the company's explicit statement of no disagreement mitigates some concern. The appointment of an internal accounting executive with three years at the company provides continuity during the transition. Investors should monitor the search process and any subsequent disclosures about the permanent CFO hire, as well as upcoming earnings calls for management commentary on the transition and any impact on financial operations or strategic initiatives.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 20, 2026, Jason O’Byrne, MBA, Executive Vice President and Chief Financial Officer of Vir Biotechnology, Inc. (Vir Bio), informed Vir Bio that he will be stepping down from his role, effective August 3, 2026, to pursue another opportunity. Mr. O’Byrne’s resignation was not because of any disagreement with Vir Bio on any matter relating to Vir Bio’s operations, policies, or practices.
Jason O'Byrne, the Executive Vice President and Chief Financial Officer, is resigning effective August 3, 2026, to pursue another opportunity. The company states his departure is not due to any disagreement with the company. A search for his successor has been initiated.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 27, 2026 · How we verify